pfizer

Pfizer to buy Allergan in $160 billion deal

By Ransdell Pierson and Bill Berkrot NEW YORK (Reuters) – Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. The acquisition, which would create the world's largest drugmaker and shift Pfizer's headquarters to Ireland, would also be the biggest-ever instance of a U….

Originally posted here:
Pfizer to buy Allergan in $160 billion deal

pfizer

Exclusive: Pfizer, Allergan CEOs agree on combined company roles – sources

Pfizer Inc and Allergan Inc chief executives have agreed on the roles they would assume in a combined company, removing one of the last hurdles to the largest ever healthcare merger, people familiar with the matter said. Pfizer CEO Ian Read will be CEO of the combined company, while Allergan CEO Brent Saunders will have another very senior role, the people said on Friday, without providing more details. Pfizer and Allergan declined to comment.

Original post:
Exclusive: Pfizer, Allergan CEOs agree on combined company roles – sources

pfizer

Starboard asks Yahoo to sell core business instead of Alibaba stake

Activist investor Starboard Value LP asked Yahoo Inc to drop plans to spin off its stake in Alibaba Group Holdings Ltd due to tax concerns, and instead urged the company to sell its core search and display advertising businesses. Yahoo's current net cash holding and the funds raised from a sale of the business could be returned to shareholders through buybacks and…

Read the original: 
Starboard asks Yahoo to sell core business instead of Alibaba stake

pfizer

Exclusive: Pfizer negotiating 2-3 percent Allergan break-up fee – sources

A break-up fee of that amount, to be paid by Pfizer if it were to walk away from the Allergan deal, would show confidence that the regulatory risk to the merger does not pose an existential threat, despite the U.S. Treasury planning this week to tighten the rules on corporate tax inversions, a key aspect of their plan. The break-up fee…

More here: 
Exclusive: Pfizer negotiating 2-3 percent Allergan break-up fee – sources

pfizer

Pfizer-Allergan deal refocuses market on U.S. tax-inversion rules

Pfizer Inc's buyout bid for Allergan Plc has financial markets on edge over a possible new move by the U.S. Treasury Department against tax-inversion deals, but the outlook for any such

Here is the original post:
Pfizer-Allergan deal refocuses market on U.S. tax-inversion rules

« Previous Page